Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 13Urinary Bladder Neoplasms 11Ovarian Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 5Colorectal Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Recurrence 2Rectal Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Bevacizumab 12olaparib 10Paclitaxel 10Carboplatin 10liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6mirvetuximab soravtansine 4Topotecan 4Taxes 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Biopsy 4pembrolizumab 3cediranib 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Gemcitabine × 30 days × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06619236 2026-06-02

RAINFOL-02

Genmab

Phase 3 Active not recruiting
448 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07604766 2026-06-02

RAINFOL-02

Genmab

Phase 3 Not yet recruiting
82 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡